Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism

Phase IV Study to Investigate the Effect of Testosterone Treatment on Paraoxonase Level in Male Patients With Hypogonadotrophic Hypogonadism

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01107067

Enrollment

Registered

2010-04-20

Start date

2008-06-30

Completion date

2009-12-31

Last updated

2010-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypogonadism

Keywords

hypogonadism, paraoxonase, Hipogonadism

Brief summary

The purpose of this study is investigating the effect of testosterone treatment on paraoxonase level in male patients with hypogonadotrophic hypogonadism

Interventions

DRUGSustanon

250 mg/21 days

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

20 Years to 25 Years

Healthy volunteers

Inclusion criteria

* Volunteers patients with hypogonadism

Exclusion criteria

* Coronary heart disease * Other pituitary/hypothalamic disorders or other non-hypogonadism diseases * None was receiving vitamins, lipid-lowering drugs, or other medications known to interfere with PON1 activity, lipid profile, or gonadal function

Design outcomes

Primary

Measure	Time frame
paraoxonase level after testosterone treatment	—

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026